Arrowgrass Capital Partners (US)’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q1
Sell
-60,000
Closed -$11.7M 332
2018
Q4
$11.7M Buy
60,000
+59,400
+9,900% +$11.6M 0.43% 67
2018
Q3
$12.4M Sell
600
-59,400
-99% -$11.7M 0.38% 75
2018
Q2
$11.1M Buy
+60,000
New +$10.6M 0.38% 75
2018
Q1
Sell
-185,600
Closed -$32.3M 152
2017
Q4
$32.3M Buy
185,600
+183,216
+7,685% +$32.4M 0.31% 64
2017
Q3
$44.5M Buy
2,384
+20
+0.8% +$3.54K 0.33% 79
2017
Q2
$40.7M Buy
2,364
+632
+36% +$103K 0.31% 86
2017
Q1
$28.4M Buy
1,732
+728
+73% +$121K 0.29% 90
2016
Q4
$14.7M Buy
1,004
+711
+243% +$107K 0.17% 127
2016
Q3
$4.89M Buy
+293
New +$49.5K 0.07% 215
2016
Q1
Sell
-350
Closed -$5.68M 397
2015
Q4
$5.68M Buy
+350
New +$55K 0.07% 151

Other funds holding AMGN

Arrowgrass Capital Partners (US)'s AMGN Position: Q3 2017 in Review

Arrowgrass Capital Partners (US) sold out of Amgen (AMGN) in Q3 2017, closing a stake of 10,904 shares — an estimated $1.93M sold.

Arrowgrass Capital Partners (US) first reported a position in AMGN in Q3 2013 and held it in 8 quarters. The position peaked at $30.8M in Q3 2014. 1,605 funds tracked by Wall St. Rank hold AMGN as of Q3 2017.

  • Arrowgrass Capital Partners (US) reported no remaining Amgen position as of Q3 2017 after selling out during the quarter.
  • Arrowgrass Capital Partners (US) sold 10,904 Amgen shares in Q3 2017, an estimated $1.93M.
  • Arrowgrass Capital Partners (US) first reported a position in Amgen in Q3 2013 and held it in 8 quarters.
  • Arrowgrass Capital Partners (US)'s Amgen position peaked at $30.8M in Q3 2014.
  • 1,605 funds tracked by Wall St. Rank held Amgen as of Q3 2017.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q3 2017, filed 14 Nov 2017.